The rare ERBB2 variant Ile654Val is associated with an increased familial breast cancer risk

Carcinogenesis

Volumn 26, Issue 3, 2005, Pages 643-647

  Frank, Bernd ^a   Hemminki, Kari ^a,b   Wirtenberger, Michael ^a   Bermejo, Justo Lorenzo ^a   Bugert, Peter ^c   Klaes, Rüdiger ^c   Schmutzler, Rita K ^d   Wappenschmidt, Barbara ^d   Bartram, Claus R ^c   Burwinkel, Barbara ^a  

^a GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^b KAROLINSKA INSTITUTE   (Sweden)

^c UNIVERSITY OF HEIDELBERG   (Germany)

^d UNIVERSITY OF COLOGNE   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; ISOLEUCINE; VALINE;

ARTICLE; BREAST CANCER; CANCER RISK; FAMILIAL CANCER; GENE OVEREXPRESSION; HAPLOTYPE; HUMAN; METASTASIS; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROGNOSIS; PROTO ONCOGENE; SINGLE NUCLEOTIDE POLYMORPHISM; STATISTICAL ANALYSIS; ADULT; AGED; BREAST TUMOR; CASE CONTROL STUDY; FEMALE; GENETIC PREDISPOSITION; GENETICS; HETEROZYGOTE DETECTION; MIDDLE AGED; RISK FACTOR;

ADULT; AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; CASE-CONTROL STUDIES; FEMALE; GENES, ERBB-2; GENETIC PREDISPOSITION TO DISEASE; HETEROZYGOTE DETECTION; HUMANS; ISOLEUCINE; MIDDLE AGED; POLYMERASE CHAIN REACTION; RISK FACTORS; VALINE;

EID: 16244422364     PISSN: 01433334     EISSN: None     Source Type: Journal    
DOI: 10.1093/carcin/bgh342     Document Type: Article

References (43)

1. Mackay, A., Jones, C., Dexter, T. et al. (2003) cDNA microarray analysis of genes associated with ERBB2 (HER/neu) overexpression in human mammary luminal epithelial cells. Oncogene, 22, 2680-2688.
2. Lichtenstein, P., Holm, N. V., Verkasalo, P.K., Iliadou, A., Kaprio, J., Koskenvuo, M., Pukkala, E., Skytthe, A. and Hemminki, K. (2000) Environmental and heritable factors in the causation of cancer-analyses of cohorts of twins from Sweden, Denmark and Finland. N. Engl. J. Med., 343, 78-85.
3. Hemminki, K. and Granstrom, C. (2003) Familial breast cancer: scope for more susceptibility genes? Breast Cancer Res. Treat., 82, 17-22.
4. Baselga, J. and Norton, L. (2002) Focus on breast cancer. Cancer Cell, 1, 319-322.
5. de Jong, M.M., Nolte, I., te Meerman, G.J., van der Graaf, W.T., Oosterwijk, J.C., Kleibeuker, J.H., Schaapveld, M. and de Vries, E.G. (2002) Genes other than BRCA1 and BRCA2 involved in breast cancer susceptibility. J. Med. Genet., 39, 225-242.
6. Antoniou, A.C., Pharoah, P.D., McMullan, G., Day, N.E., Ponder, B.A. and Easton, D. (2001) Evidence for further breast cancer susceptibility genes in addition to BRCA1 and BRCA2 in a population-based study. Genet. Epidemiol., 21, 1-18.
7. Tommasi, S., Giannella, C., Mangia, A., Primavera, A.T., Paradiso, A. and Schittulli, F. (1996) HER-2/neu, c-myc and cyclin A in human breast cancer. Int. J. Oncol, 9, 111-115.
8. Tommasi, S., Fedele, V., Crapolicchio, A., Bellizzi, A., Paradiso, A. and Reshkin, S.J. (2003) ErbB2 and the antimetastatic nm23/NDP kinase in regulating serum induced breast cancer invasion. Int. J. Mol. Med., 12, 131-135.
9. Schechter, A.L., Stern, D.F., Vaidyanathan, L., Decker, S.J., Drebin, J.A., Greene, M.I. and Weinberg, R.A. (1984) The neu oncogene: an er6-B-related gene encoding a 185,000-Mr tumour antigen. Nature, 312, 513-516.
10. King, C.R., Kraus, M.H. and Aaronson, S.A. (1985) Amplification of a novel v-erbB-related gene in a human mammary carcinoma. Science, 229, 974-976.
11. Bargmann, C.I., Hung, M.C. and Weinberg, R.A. (1986) The neu oncogene encodes an epidermal growth factor receptor-related protein. Nature, 319, 226-230.
12. Akiyama, T., Sudo, C., Ogawara, H., Toyoshima, K. and Yamamoto, T. (1986) The product of the human c-erbB-2 gene: a 185-kilodalton glycoprotein with tyrosine kinase activity. Science, 232, 1644-1646.
13. Hynes, N.E. and Stern, D.F. (1994) The biology of erbB-2/neu/HER2 and its role in cancer. Biochim. Biophys. Acta, 1198, 165-184.
14. Mendrola, J.M, Berger, M.B., King, M.C. and Lemmon, M.A. (2002) The single transmembrane domains of ErbB receptors self-associate in cell membranes. J. Biol. Chem., 277, 4704-4712.
15. Fleishman, S.J., Schlessinger, J. and Ben-Tal, N. (2002) A putative molecular, activation switch in the transmembrane domain of erbb2. Proc. Natl Acad. Sci. USA, 99, 15937-15940.
16. Chen, C.H., Chernis, G.A., Hoang, V.Q. and Landgraf, R. (2003) Inhibition of heregulin signaling by an aptamer that preferentially binds to the oligomeric form of human epidermal growth factor receptor-3. Proc. Natl Acad. Sci. USA, 100, 9226-9231.
17. Yokota, J., Yamamoto, T., Miyajima, N., Toyoshima, K., Nomura, N., Sakmoto, H., Yoshida, T., Terada, M. and Sugimura, T. (1988) Genetic alterations of the c-erbB-2 oncogene occur frequently in tubular adenocarcinoma of the stomach and are often accompanied by amplification of the v-erbA homologue. Oncogene, 2, 283-287.
18. Slamon, D.J., Godolphin, W., Jones, L.A. et al. (1989) Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science, 244, 707-712.
19. Schneider, P.M, Hunh, M.C., Chiocca, S.M, Manning, I., Zhao, X.Y., Fang, K. and Roth, J.A. (1989) Differential expression of the c-erbB-2 gene in human small cell and non-small cell lung cancer. Cancer Res., 49, 4968-4971.
20. Berchuck, A., Kamel, A., Whitaker, R. et al. (1990) Overexpression of HER-2/neu is associated with poor survival in advanced epithelial ovarian cancer. Cancer Res., 50, 4087-4091.
21. Dougall, W.C, Qian, X. and Greene, M.I. (1993) Interaction of the neu/p185 and EGF receptor tyrosine kinases: implications for cellular transformation and tumor therapy. J. Cell Biochem., 53, 61-73.
22. Revillion, F., Bonneterre, J. and Peyrat, J.P. (1998) ERBB2 oncogene in human breast cancer and its clinical significance. Eur. J. Cancer, 34, 791-808.
23. Akisik, E. and Dalay, N. (2004) Estrogen receptor codon 594 and HER2 codon 655 polymorphisms and breast cancer risk. Exp. Mol. Pathol., 76, 260-263.
24. Xie, D., Shu, X.O., Deng, Z., Wen, W.Q., Creek, K.E., Dai, Q., Gao, Y.T., Jin, F. and Zheng, W. (2000) Population-based, case control study of HER2 genetic polymorphism and breast cancer risk. J. Natl Cancer Inst., 92, 412-417.
25. Ameyaw, M., Thornton, N. and McLeod, H.L. (2000) Re: Population-based, case control study of HER2 genetic polymorphism and breast cancer risk. J. Natl Cancer Inst., 92, 1947.
26. Baxter, S.W. and Campbell, I.G. (2001) Re: Population-based, case control study of HER2 genetic polymorphism and breast cancer risk. J. Natl Cancer Inst., 93, 557-558.
27. Keshava, C., McCanlies, E.C., Keshava, N., Wolff, M.S. and Weston, A. (2001) Distribution of HER2(V655) genotypes in breast cancer cases and controls in the United States. Cancer Lett., 173, 37-41.
28. McKean-Cowdin, R., Kolonel, L.N., Press, M.F., Pike, M.C. and Henderson, B.E. (2001) Germ-line HER-2 variant and breast cancer risk by stage of disease. Cancer Res., 61, 8393-8394.
29. Wang-Gohrke, S. and Chang-Claude J. (2001) Re: Population-based, case control study of HER2 genetic polymorphism and breast cancer risk. J. Natl Cancer Inst., 93, 1657-1659.
30. Ameyaw, M.M., Tayeb, M., Thornton, N., Folayan, G., Tariq, M., Mobarek, A., Evans, D.A., Ofori-Ajei, D. and McLead, H.L. (2002) Ethnic variation in the HER-2 codon 655 genetic polymorphism previously associated with breast cancer. J. Hum. Genet., 47, 172-175.
31. Hishida, A., Hamajima, N., Iwata, H., Matsuo, K., Hirose, K., Emi, N. and Tajima, K. (2002) Re: Population-based, case control study of HER2 genetic polymorphism and breast cancer risk. J. Natl Cancer Inst., 94, 1807-1808.
32. Milikan, R., Eaton, A., Worley, K. et al. (2003) HER2 codon 655 and risk of breast cancer in African Americans and whites. Breast Cancer Res. Treat., 79, 355-364.
33. Montgomery, K.G., Gertig, D.M., Baxter, S.W. et al. (2003) The HEK1 1655V polymorphism and risk of breast cancer in women < 40 years. Cancer Epidemiol. Biomarkers Prev., 12, 1109-1111.
34. Rutter, J.L., Chatterjee, N., Wacholder, S. and Struewing, J. (2003) The HER2 1655V polymorphism and breast cancer risk in Ashkenazim. Epidemiology, 14, 694-700.
35. Meindl, A. and the German Consortium for Hereditary Breast and Ovarian Cancer (2002) Comprehensive analysis of 989 patients with breast or ovarian cancer provides BRCA1 and BRCA2 mutation profiles and frequencies for the German population. Int. J. Cancer, 97, 472-480.
36. Stephens, M., Smith, N.J. and Donnelly, P. (2001) A new statistical method for haplotype reconstruction from population data. Am. J. Hum. Genet., 68, 978-989.
37. Tommasi, S., Fedele, V., Lacalamita, R., Crapolicchio, A., Perlino, E., Bellizzi, A. and Paradiso, A. (2004) Molecular and functional characteristics of erbB2 in normal and cancer breast cells. Cancer Lett., 209, 215-222.
38. Houlston, R.S. and Peto, J. (2003) The future of association studies of common cancers. Hum. Genet., 112, 434-435.
39. Antoniou, A.C. and Easton, D.F. (2003) Polygenic inheritance of breast cancer: implication for design of association studies. Genet. Epidemiol., 25, 190-202.
40. Amundadottir, L.T. and Leder, P. (1998) Signal transduction pathways activated and required for mammary carcinogenesis in response to specific oncogenes. Oncogene, 16, 737-746.
41. Laferriere, J., Houle, F. and Huot, J. (2002) Regulation of the metastatic process by E-selectin and stress-activated protein kinase-2/p38. Ann. N. Y. Acad. Sci., 973, 562-572.
42. Takano, K., Ogasahara, K., Kaneda, H., Yamagata, Y., Fujii, S., Kanaya, E., Kikuchi, M., Oobatake, M. and Yutani, K. (1995) Contribution of hydrophobic residues to the stability of human lysozyme: calorimetric studies and X-ray structural analysis of the five isoleucine to valine mutants. J. Mol. Biol., 254, 62-76.
43. Bargmann, C.I. and Weinberg, R.A. (1988) Oncogenic activation of the neu-encoded receptor protein by point mutation and deletion. EMBO J., 7, 2043-2052.